Loading
Ferroptosis and Cancer Prognosis · Journal article
Biomedicines · August 13, 2026
Encouraging direction, but not yet definitive.
This retrospective multicenter study identified the CALLY index and SII as independent prognostic biomarkers in advanced NSCLC treated with first-line immunotherapy, with CALLY showing consistent association with clinical benefit, PFS, and OS. The findings are clinically plausible and statistically significant but require prospective validation and external replication before clinical implementation.
Multicenter retrospective cohort study. Advanced non-small cell lung cancer patients treated with first-line immune checkpoint inhibitor-based therapy at multiple centers.. Intervention: First-line immune checkpoint inhibitor-based therapy (ICI monotherapy, chemoimmunotherapy, or dual ICI).. Compared with: High vs. low baseline values of systemic inflammation-based biomarkers (PIV, SII, LIPI, CALLY index).. n = 161. Multicenter (specific countries/centres not stated in the source text)..
High CALLY index associated with higher clinical benefit rate (82.1% vs. 59.5%; p = 0.015), longer PFS (14.95 vs. 7.13 months; p = 0.002), and longer OS (25.79 vs. 13.24 months; p = 0.003). In multivariable analysis, high CALLY index independently associated with improved PFS (HR = 0.52, p = 0.006) and OS (HR = 0.53, p = 0.010). High SII independently associated with poorer PFS (HR = 1.74, p = 0.021) and OS (HR = 1.90, p = 0.009) in multivariable analysis.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians may consider CALLY index and SII as candidate prognostic markers to stratify immunotherapy-treated NSCLC patients, but prospective validation and standardization of cutoff values are necessary before routine clinical use. The findings support further investigation into inflammation-based biomarkers for patient selection and outcome prediction.
A sound retrospective multicenter study identifying independent prognostic biomarkers (CALLY index and SII) in advanced NSCLC treated with first-line immunotherapy, with clear hazard ratios and p-values, but limited by retrospective design and moderate sample size without external validation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians may consider CALLY index and SII as candidate prognostic markers to stratify immunotherapy-treated NSCLC patients, but prospective validation and standardization of cutoff values are necessary before routine clinical use. The findings support further investigation into inflammation-based biomarkers for patient selection and outcome prediction.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: We assessed the prognostic value of the pan-immune–inflammation value (PIV), systemic immune–inflammation index (SII), lung immune prognostic index (LIPI), and c-reactive protein–albumin–lymphocyte (CALLY) index in advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitor (ICI)-based therapy. Methods: This multicenter retrospective study included 161 patients who received ICI monotherapy, chemoimmunotherapy, or dual ICI therapy. The objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression models. Results: A high CALLY index was associated with a significantly higher CBR (82.1% vs. 59.5%; p = 0.015), longer PFS (14.95 vs. 7.13 months; p = 0.002), and longer OS (25.79 vs. 13.24 months; p = 0.003). In the multivariable analyses, a high CALLY index remained independently associated with improved PFS (HR = 0.52, p = 0.006) and OS (HR = 0.53, p = 0.010), whereas a high SII was independently associated with poorer PFS (HR = 1.74, p = 0.021) and OS (HR = 1.90, p = 0.009). PIV and LIPI were not independently associated with survival outcomes. Conclusions: SII and the CALLY index emerged as independent prognostic biomarkers in advanced NSCLC receiving first-line immunotherapy-based treatment. The CALLY index showed the strongest and most consistent association with clinical benefit, PFS, and OS.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.